US 8957047
GLA monotherapy for use in cancer treatment
granted A61KA61K2039/505A61K31/7016
Quick answer
US patent 8957047 (GLA monotherapy for use in cancer treatment) held by IMMUNE DESIGN CORP. expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- IMMUNE DESIGN CORP.
- Grant date
- Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K2039/505, A61K31/7016, A61K31/7024, A61K31/7028